Legal & General Group
EIGR

Legal & General Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Legal & General Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-169
Closed -$4.54K – 3556
2023
Q1 		$4.54K Hold
169
– – ﹤0.01% 3312
2022
Q4 		$5.98K Hold
169
– – ﹤0.01% 3333
2022
Q3 		$38K Buy
169
+25
+17% +$6.14K ﹤0.01% 3044
2022
Q2 		$27K Buy
144
+55
+62% +$11.1K ﹤0.01% 3142
2022
Q1 		$22K Hold
89
– – ﹤0.01% 3222
2021
Q4 		$14K Hold
89
– – ﹤0.01% 3393
2021
Q3 		$18K Hold
89
– – ﹤0.01% 3321
2021
Q2 		$23K Sell
89
-29
-25% -$7.24K ﹤0.01% 3253
2021
Q1 		$31K Sell
118
-4
-3% -$1.26K ﹤0.01% 2983
2020
Q4 		$45K Buy
122
+11
+10% +$3.15K ﹤0.01% 2832
2020
Q3 		$27K Sell
111
-21
-16% -$6.53K ﹤0.01% 2885
2020
Q2 		$38K Sell
132
-1
-0.8% -$295 ﹤0.01% 2809
2020
Q1 		$27K Sell
133
-28
-17% -$8.93K ﹤0.01% 2809
2019
Q4 		$72K Buy
161
+31
+24% +$11K ﹤0.01% 2692
2019
Q3 		$40K Hold
130
– – ﹤0.01% 2833
2019
Q2 		$41K Buy
+130
New +$45K ﹤0.01% 2860
2017
Q2 		– Sell
-31
Closed -$10K – 3394
2017
Q1 		$10K Hold
31
– – ﹤0.01% 3195
2016
Q4 		$10K Buy
+31
New +$11.4K ﹤0.01% 3215

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Legal & General Group's EIGR Position: Q2 2023 in Review

Legal & General Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 169 shares — an estimated $4.54K sold.

Legal & General Group first reported a position in EIGR in Q4 2016 and held it in 18 quarters. The position peaked at $72K in Q4 2019. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • Legal & General Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 169 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $4.54K.
  • Legal & General Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 18 quarters.
  • Legal & General Group's Eiger BioPharmaceuticals, Inc. position peaked at $72K in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.